RecipientAmountDeal / Technology HighlightLead InvestorsDeal TypeCountry
Bioverativ Inc $11,600 millionAcquisition of All Outstanding SharesSanofiAcquisition United States
Juno Therapeutics Inc $9,000 millionAcquisition Will Add Novel Scientific Platform and Manufacturing Expertise to Celgene's Research and Operational CapabilitiesCelgene CorporationAcquisition United States
Impact Biomedicines $7,000 millionAddition of Fedratinib to Its Pipeline of Novel Therapies for Hematologic MalignanciesCelgene CorporationAcquisition United States
Ablynx$4,800 millionAcquisition of All Outstanding Ordinary SharesSanofiAcquisition Belgium
Regeneron $1,640 millionTo Accelerate and Expand Investment for Cemiplimab and Dupilumab Development ProgramsSanofiExpansion of Agreement United States
Sirtex Medical Limited$1,283 millionTo expand Varian's cancer care portfolionVarian Medical SystemsAcquisition Australia
Arvinas LLC$830 millionFor the discovery and development of drug candidates using Arvinas’ proprietary PROTAC (PROteolysis TArgeting Chimeras) Platform, a novel technology used to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.Pfizer IncResearch Collaboration and License Agreement United States
Cascadian Therapeutics$614 millionEnhances Seattle Genetics’ Portfolio of Solid Tumor Programs with Potential Rapid Registrational PathwaysSeattle GeneticsAcquisition United States
MacroGenics$380 millionTo Develop a Novel Bispecific MoleculeRoche Research Collaboration United States
Addex Pharma$330 millionTo Accelerate Development of GABAB PAMs for Addiction Disorder TreatmentsIndivior PLCStrategic CollaborationSwitzerland
Unknown$300 millionTo invest in promising early stage start-up companies, focusing on regenerative medicine, infectious diseases and immune oncology among others, as well as growing the portfolio in the U.S. and opening doors for the BIVF in digital healthBoehringer Ingelheim Venture Fund (BIVF)Series A Financing
CardioSert Ltd$300 millionTo Acquire Novel Technology to Enhance Existing Technology Platforms and Strengthen Patent PortfolioMicrobot Medical IncAcquisition United States
BioNTech AG$270 millionTo advance its clinical pipeline of individualized immunotherapies covering a number of new approaches including mRNA and CAR-T / T-Cell receptors for the treatment of cancer and other diseases with high medical needRedmile Group, Janus Henderson Investors, Invus etcSeries A FinancingGermany
REGENXBIO Inc$260 millionThe Development and Commercialization of Treatments for Spinal Muscular AtrophyAveXisLicense Agreement United States
Mitobridge Inc $225 millionThe transaction accelerates Astellas’ research and development in diseases associated with mitochondrial dysfunctions and will enable the delivery of innovative new treatment options to patients Astellas Pharma Acquisition United States
Jiangsu Hengrui Medicine $223 millionDevelopment and Commercialization Partnership for Novel Immune-Mediated Dermatology Therapy Using SHR0302, for the treatment of dermatology disorderArcutis IncLicense AgreementChina
Karyopharm Therapeutics Inc$217 millionTo acquire Karyopharm’s investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions. Biogen Agreement United States
Neomed Institute$202 million To advance NEOMED's NEO1940 novel, peripherally restricted, CB1/CB2 agonist, clinic-ready drug candidate for the treatment of patients suffering from cancer and anorexia/weight loss associated with cancerArtelo BiosciencesLicense AgreementCanada
Teva Pharmaceuticals International $200 millionTo develop, manufacture and commercialize eptinezumab in the U.S. and worldwide, excluding Japan and KoreaAlder BioPharmaceuticalsGlobal License AgreementGermany
Spark Therapeutics$170 millionTo develop and commercialize investigational voretigene neparvovec outside the U.S.Novartis Pharmaceuticals License Agreement United States
Adapsyn Bioscience$162 millionTo Advance its Small Molecule Natural Product Platform and Pipeline; Announces Research Collaboration with PfizerPfizer R&D Innovate and Genesys Capital Financing Canada
Mallinckrodt plc$153 million To Broaden Portfolio of Innovative Surgical ProductsBaxter International IncAcquisition United Kingdom
Denali Therapeutics $150 millionTo Develop and Commercialize Therapies for Neurodegenerative DiseasesTakeda Pharmaceutical CompanyCollaboration Agreement United States
STAT-Dx$147 millionTo launch a next-generation, fully integrated multiplex platform for syndromic disease testingQIAGEN Acquisition United States
Santa Monica (Gilead Sciences)$135 millionUnder contract to buy the 160,000-square-foot flex building at 1800 Stewart St. from Agensys, Inc., a biotechnology and cancer-research company owned by Tokyo’s Astellas Pharma, Inc.Kite Pharma Leasehold Agreement United States
Tmunity Therapeutics$100 millionTo Advance Portfolio of Next-Generation T cell Immunotherapies to Transform the Treatment of CancerPing An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences, IncetcSeries A Financing United States
Receptos Inc$100 millionFocused on Discovering and Developing a Pipeline of Novel and Differentiated Drug CandidatesOmega Funds Venture Partners and Series A Financing United States
KBP Biosciences$76 millionEstablished China Biotechnology Company with Deep R&D Pipeline,Proceeds will also advance clinical development of lead candidate, KBP-5074, through Phase 2b trials for cardiovascular disease Advantech Capital and SDIC Venture Capital etcSeries A Financing United States
Data Sciences International Inc$70 millionTo acquire 100% of the outstanding stock Harvard Bioscience IncAcquisition United States
Centrexion Therapeutics Corporation$67 million Launching Phase 3 Program for CNTX 4975 in Knee Osteoarthritis Pain in 2018, Financing Brings Together Strong Syndicate of Investors to Advance Clinical Pipeline of Non Opioid Chronic Pain Therapies New Enterprise AssociatesSeries D Financing United States
Novartis$65 millionTo Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED TherapeuticsBridgeBio Pharma License Agreement United States
Eureka Therapeutics$60 millionTo Advance Proprietary ARTEMIS™ T Cell Receptor Platform For Safer T Cell TherapiesAcorn Pacific VenturesSeries D Financing United States
Pandion Therapeutics Inc$58 million To Advance Tissue-Specific Immune Modulator Drugs for Autoimmune and Inflammatory DiseasesVersant Ventures and Roche Venture Fund SR One and BioInnovation CapitalSeries A financing United States
Alnylam Pharmaceuticals Inc$50 millionEnables Streamlined Development and Optimization of Commercial Opportunities for ATTR Amyloidosis and Hemophilia ProgramsSanofiStrategic RestructuringUnited States
Scholar Rock$47 millionTo Advance Innovative Pipeline for SMA, Immuno-Oncology, Fibrosis, and Iron-Restricted AnemiasInvus, new investor Redmile GroupSeries C Financing United States
Neurogastrx Inc$45 millionTo fill out the management team and reach proof of concept with its lead asset, NG-101, which is intended to treat gastroparesis, a debilitating functional GI disorder 5AM Ventures, OrbiMed Advisors and venBio PartnersSeries A financing United States
Stoke Therapeutics$40 millionTo support the further advancement of multiple pre-clinical development programsApple Tree PartnersSeries A Financing United States
Elstar Therapeutics$39 millionTo Support Development of its Universal Targeted Immunotherapy Platform (UniTITM)Apple Tree PartnersSeries A Financing United States
Enterome$38.5 millionTo treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications Seventure, Health for Life Capital, Lundbeck Fonden Ventures, Omnes Capital & Nestle Health Science Series D FinancingFrance
Bonti$36 million To continue developing EB-001, a unique botulinum neurotoxin, for its targeted therapeutic and aesthetic indications with significant addressable unmet needs in patientsUnknownInvestment United States
Alliqua Biomedical $29.0 millionCelularity will acquire all of the property, assets and rights relating to the Company’s advanced biologic wound care business - including Biovance® amniotic membrane allograft and Interfyl® Human Connective Tissue Matrix - and the Company’s UltraMist®CelularityPurchase Agreement United States
Corbus Pharmaceuticals $25 million To Support Phase 2b Clinical Study of LenabasumCystic Fibrosis Foundation Development Award United States
Inovio Pharmaceuticals $23 millionTo Develop and Commercialize VGX-3100 in Greater ChinaApolloBio Corporation Collaboration Agreement United States
NexImmune$23 millionTo Advance Endogenous Cellular ImmunoTherapy into Clinical DevelopmentArrowMark Partners and Barer & Son CapitalSeries A Financing United States
Oculis $20.3 millionTo Advance Breakthrough Treatments for Ophthalmic DiseasesBay City Capital, Novartis Venture Fund and Pivotal bioVenture PartnersSeries B FinancingSwitzerland
KWS BioTest$20 millionThe addition of KWS enhances Charles River’s discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.Charles River LaboratoriesAcquisition United Kingdom
Enochian Biopharma $20 million Enochian's technology will enhance DanDrit's research and development efforts in cellular therapy and add to its pipeline, which also includes cellular immuneoncology products for the prevention of relapse of metastatic colon cancer after resection and chemotherap DanDrit Biotech USAAcquisition United States
PharmaIN Corporation$17 millionPharmaIN which has innovative platform technologies for drug discovery of various molecules including peptides, proteins and small moleculesShionogi CorpCollaboration Agreement United States
BIAL $15.52 millionFor the importation, packaging and commercialization of Opicapone in China (excluding Hong Kong, Macao and Taiwan).Jiangsu Wanbang Biopharmaceutical Group (subs- Shanghai Fosun Pharmaceutical (Group) )License AgreementPortugal
Carmot Therapeutics$15 millionThe funds will support development of the company’s lead type 2 diabetes drug, a dual GLP-1R/GIPR agonist, through early clinical proof of conceptHorizons Ventures Series B Financing United States
OWKIN $13.1 millionFunding will expand OWKIN Socrates, the first data driven discovery platform for clinical researchOtium VentureSeries A Financing United States
Dosecann Inc$11.5 millionDosecann investment to leverage existing synergies within MMJ portfolio MMJ PhytoTech LimitedAcquisition Canada
Pherecydes Pharma$10.3 millionTo produce phages for compassionate use (ATU or Temporary Authorization for Use) in accordance with GMP. Pherecydes will move two programs into the clinical phase in 2018 and 2019Go Capital, with participation from Omnes Capital etcSeries B FinancingFrance
Pisgah Labs Inc$9.65 millionAcquisition of 100% share capital of Pisgah Labs Inc North Carolina. USA by Company's subsidiaries Ipca Pharmaceutical Inc, USA (subs Onyx Scientific Ltd)Acquisition United States
Skyhawk Therapeutics Inc$8 millionTo Advance Its Novel Platform and Portfolio of Small Molecules That Correct RNA ExpressionTim Disney, The Duke of Bedford, Alexandria Venture Investments & other undisclosed private investorsSeed Funding United States
GT Biopharma Inc $7.1 millionTo advance its immuno-oncology programs, which are based on the company's proprietary Tri and Tetra-specific Natural Killer Cell Engagers (TriKEs™ and TetraKEs) and bispecific antibody-drug conjugate (ADC) platforms, neurology (CNS) pipeline progress, and for general corporate purposesOppenheimer & Co IncDefinitive Agreements United States
Piedmont Pharmaceuticals LLC$7.0 millionAcquires Global ex-U.S. Product Rights and existing Royalty Streams to Resultz®Nuvo Pharmaceuticals IncAcquisition United States
Cellect Biotechnology $4 million Company will issue 484,848 registered American Depository Shares (ADSs) at a purchase price of $8.25 per ADS in a registered direct offering. HC Wainwright & CoDirect OfferingIsrael
Level Brands Inc$2 millionTo develop consumer products for kathy ireland® Health & Wellness, a licensor to Level Brands, and for Level Brands subsidiary I’M1, the company’s lifestyle brand for menIsodiol International IncLicense Agreement United States
Metrion Biosciences $0.84 millionIndustry-leading ion channel SyndicateRoomInvestmentUnited Kingdom
Serum Institute of India Pvt LtdUndisclosedTo manufacture & sell fully liquid Whole cell Pertussis (wP) and Salk based Injectable Polio Vaccine (IPV) based Hexavalent vaccine (DTwP-HepB-Hib-IPV)Panacea Biotec LtdCollaboration Agreement India
FDAUndisclosedRegarding the design of its next study of lenabasum (formerly known as anabasum),on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary EndpointCorbus Pharmaceuticals Research AgreementUnited States
BioconUndisclosedTo develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.Sandoz Global PartnershipIndia
Distributed Bio IncUndisclosedDistributed Bio will use its proprietary SuperHuman antibody library platform to discover therapeutic ready pre-optimized antibodies against multiple Pandion targetsPandion Therapeutics IncMulti-target PartnershipUnited States
Aeterna Zentaris IncUndisclosedTo carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada.Strongbridge Biopharma plcLicense and Assignment AgreementUnited States
Syndax Pharmaceuticals IncUndisclosedTo Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast CancerGenentechClinical CollaborationUnited States
TiGenixUndisclosedExpands Takeda’s Late Stage Pipeline and Leadership in GastroenterologyTakeda Pharmaceutical CompanyAcquisition Extends Existing CollaborationUnited States
Unipharm UndisclosedTo acquire a range of over-the-counter (OTC) medicines, Reinforce Strong Patient Focused Business in RussiaTakeda Pharmaceutical CompanyAcquisitionUzbekistan
Generation BioUndisclosedDeveloping GeneWave™ - A Breakthrough Platform for Re-Dosable Gene Therapy Atlas VentureLaunch United States
Boehringer Ingelheim UndisclosedTwo companies have entered into a commercial supply agreement for tislelizumab, BeiGene’s investigational anti-PD-1 antibodyBeiGene Commercial Supply AgreementGermany
TransPerfect Life SciencesUndisclosedTo support clinical trials and product development for the biopharmaceutical industry, Trial Interactive e-clinical and eTMF technologyAdvarraPartnershipUnited States
CorePharmaUndisclosedIt provides us with a strong and reputable manufacturing infrastructure and an ideal location with headquarters in MiddlesexImpax Laboratories IncAcquisition United States
Boston University School of Medicine UndisclosedTo Study the Effects of Alzheimer's Disease-associated Genetic Variants on BrainEisai Research CollaborationUnited States
Porton Pharma SolutionsUndisclosed To expands the reach of our offerings to provide fully integrated API and drug product development and manufacturing solutions to our clients for seamless advancement of their programs from discovery to clinical developmentBioDuro Cooperation Agreement China
Prime TherapeuticsUndisclosed Outcomes-Based Contract for Jardiance®(empagliflozin) Boehringer IngelheimOutcomes-Based Contract United States
Sandoz IncUndisclosedANDA Portfolio to build a robust pipeline and commercialize quality drug candidates in China, including entecavir, an antiviral medication used in the treatment of hepatitis B viral infection (“HBV”)CASI PharmaceuticalsAcquisition United States
ChemDiv IncUndisclosedTo extending it into finding potent anti-infective drug candidates & to deliver a pipeline of novel high-quality hit series in the area of infectious diseasesJanssen Research & DevelopmentCollaboration Agreement United States
Eisai CoUndisclosedFor potential anticancer agent E7046 prostaglandin E2 (PGE2)receptor type EP4 antagonistAdlai Nortye BiopharmaLicense AgreementJapan
Tabuk PharmaceuticalsUndisclosedTo commercialize and distribute Ivy ODF in the Kingdom of Saudi Arabia, the Gulf and Levant areaRed OTC Development GmbHLicensing Agreement & Supply Agreement Saudi Arabia
UnknownUndisclosedTo Develop and Market Dextromethadone for Treatment of Disorders of the Nervous SystemRelmada Therapeutics Acquisition
Compass TherapeuticsUndisclosedFor the semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of a therapeutic targeting solid tumors. Semi-mechanistic PK/PD models will be developed for mouse, cynomolgus monkey, and human speciesApplied BioMathCollaboration Agreement United States
OraPharma (Valeant Pharmaceuticals International)UndisclosedBegins Promotion of SPRIX®( ketorolac tromethamine) Nasal SprayEgalet CorporationPartnershipUnited States
ABL Europe & ABL IncUndisclosedTo Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies & to Manufacture Clinical Material for SillaJen's JX-970SillaJen IncCollaboration Agreement France & United States
Genentech (Roche Group)UndisclosedTo Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast CancerSyndax PharmaceuticalsClinical Collaboration United States
Syapse UndisclosedTo Advance Precision Medicine in Oncology, Companies work jointly to develop software products and analytics solutions Roche Collaboration Agreement United States
SyapseUndisclosedPartnership will democratize access to clinical trials and help community health systems find and enroll eligible patients at unprecedented scaleMedidata PartnershipUnited States
GE HealthcareUndisclosed To jointly develop and co-market digital clinical decision support solutions. The partnership will initially focus on products that accelerate and improve individualised treatment options for cancer and critical care patientsRoche PartnershipUnited States
Livongo HealthUndisclosedTo study real-world evidence and develop new insights to reduce the burden on people living with diabetesEli Lilly and Company Collaboration Agreement United States
Intec PharmaUndisclosedTo explore using the Accordion Pill platform for a proprietary Novartis compoundNovartis PharmaceuticalsCollaboration Agreement Israel
Pfizer IncUndisclosedFocused on optimizing BLI’s proprietary BeaconTM Optofluidic platform with the goal of helping to accelerate Pfizer’s monoclonal antibody (mAb) discovery and gene editing workflowsBerkeley Lights, Inc Collaboration & License Agreement United States
Corsair Pharma UndisclosedTo Advance Novel Treprostinil ProdrugsUnited Therapeutics CorporationStrategic Collaboration United States
BASES Pharmaceutical UndisclosedThese new assets and expertise complement the rest of our forecasting offeringsZS AssociatesAcquisition
PharmaMarUndisclosed For the marine-derived anticancer drug Aplidin® (plitidepsin) in Israel and the territory known as the Palestinian AuthorityMegapharm LtdLicense AgreementSpain
Japan Tobacco IncUndisclosedAcquires rights to small molecule potassium channel inhibitorsMetrion BiosciencesAcquisition Japan
Concept Life Sciences GroupUndisclosedAcquisition increases Concept’s global reach and supports growth strategySpectris plcAcquisition United Kingdom
Tsing Hua Testing & AnalysisUndisclosedTsing Hua provides a comprehensive suite of testing services for wastewater, drinking water, ground water, fuel gas, ambient air, noise, soil and waste to a broad range of customers in TaiwanEurofins ScientificAcquisition Taiwan
Eurofins ScientificUndisclosedSelcia provides Eurofins with an entry into the custom radiolabelling and innovative pre-clinical, integrated drug discovery services markets, both exciting new business streams for Eurofins offering significant growth potentialSelcia LimitedAcquisition Luxembourg
UCL Great Ormond Street Institute of Child HealthUndisclosedTo Develop Novel Gene Therapies for Blood-based DisordersSynpromicsPartnershipUnited Kingdom
Selcia LimitedUndisclosedOn license terms under which Cypralis will hold exclusive development and commercialization rights to certain jointly-owned ‘cyprolides’ for acute and chronic degenerative diseasesCypralis & Gilead SciencesCollaboration Agreement United Kingdom
Mydent International Enterprises CorpUndisclosedThe DEFEND brand has developed a reputation for high quality at great value that resonates well with clinicians and dental organizations around the worldYoung InnovationsAcquisition United States
Solid Form Solutions LtdUndisclosedCombination Strengthens CDMO’s Early Phase Drug Development OfferingAvista Pharma Solutions IncAcquisition Scotland
TP3 GlobalUndisclosedTo expand worldwide presence and strengthen product portfolioSoftbox Acquisition United Kingdom
BioCryst PharmaceuticalsUndisclosedTo form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases Idera PharmaceuticalsDefinitive Merger AgreementUnited States
Elion LabsUndisclosedTo Further Expand Industry-Leading Biophysical and Analytical Characterization CapabilitiesKBI Biopharma IncAcquisition United States
Arno TherapeuticsUndisclosedThe Acquisition of Apristor™ (Onapristone XR), an Investigational Phase 2 Drug for Metastatic Breast CancerContext TherapeuticsAcquisition United States
DrugScan IncUndisclosedTo lead the way on the front lines of the opioid crisis here and across the nationACM Global Laboratories (Rochester Regional Health) Strategic AcquisitionUnited States
Maine Biotechnology Services (MBS)UndisclosedThe addition of over 80 new antibodies to its growing product portfolio, as well as custom antibody development servicesBBI SolutionsAcquisition United States
Accurate Medical TherapeuticsUndisclosedAcceleration of the interventional radiology strategyGuerbet Acquisition Israel
Cork (Luxcel Biosciences )UndisclosedThis acquisition expands Agilent's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readersAgilent Technologies IncAcquisition Ireland
Merus Undisclosed To develop and commercialize in China three bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform in the area of immuno-oncology.Simcere Pharmaceutical GroupCollaboration Agreement Netherlands
Radiant GenomicsUndisclosedThe addition brings Radiant Genomics’ leading-edge metagenomic technologies and accompanying genetic libraries to Zymergen’s core platform, accelerating Zymergen’s ability to identify and commercialize novel molecules used in a range of industriesZymergenAcquisition United States
Vita LiberataUndisclosedAdds Leading, All-Natural Product Line in Sunless Tanning to Crown’s Dermatology PortfolioCrown Laboratories Inc & Hildred Capital Partners LLCAcquisition Ireland
Angiochem IncUndisclosedTo develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancerXinogen License AgreementCanada
Zyga TechnologyUndisclosedAcquisition Expands Spine Franchise Portfolio and Accelerates Growth Potential; Zyga Technology Provides Innovative SImmetry® Sacroiliac Joint Fusion SystemRTI Surgical IncAcquisition United States
Rocket PharmaceuticalsUndisclosedIt focus on advancing a pipeline of gene therapy programs targeting rare and undertreated diseases. Inotek Pharmaceuticals CorporationMergerUnited States
Array BioPharmaUndisclosedTo develop, manufacture and commercialise varlitinibASLAN PharmaceuticalsAcquisition United States
Viamet Pharmaceuticals UndisclosedTo advance the clinical development of VT 1161 for the treatment of RVVC and Onychomycosis NovaQuest Capital Management LLCAcquisition United States
Glen Research Corporation (“Glen Research”)UndisclosedGlen Research will continue its focus on superior customer service as part of the Maravai portfolioMaravai LifeSciences & GTCR Acquisition United States
Inovio PharmaceuticalsUndisclosedAdvances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approachesThe Parker InstituteClinical Collaboration AgreementUnited States
Pfizer IncUndisclosedTo Evaluate Investigational Combination of Yescarta™ (Axicabtagene Ciloleucel) and Pfizer’s Utomilumab in Large B-Cell LymphomaKite PharmaClinical Collaboration United States
Dracen PharmaceuticalsUndisclosedTo develop its platform of anticancer therapiesThe Johns Hopkins University (Baltimore) & The Institute of Organic Chemistry and Biochemistry (Prague) License AgreementUnited States
Bio-Pharm Inc UndisclosedTo expand the BPI facilities including R&D capabilities and will increase the number of product filings from BPITorrent Pharmaceuticals LimitedAcquisition United States
Metanomics Health GmbHUndisclosedTo Create a New Global Leader in Metabolomics and Early Disease DetectionBIOCRATES Life Sciences AGAcquisition Germany